arrow
A

Alexis Talbot

INSERM
H指数:18
被引数:1,454

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)

通过大型开放式网络课程(MOOC)为多发性骨髓瘤患者及照护者提供以患者为中心的教育:法国多发性骨髓瘤患者协会(AF3M)和法语骨髓瘤协作组(IFM)关于知识增长的描述性研究

2026-01-010
PRE
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

35年专注于高剂量疗法和自体干细胞移植的学术研究:法国骨髓瘤研究组(IFM)的经验

2025-10-240
OA
Integrated epigenetic and genetic programming of primary human T cells

整合表观遗传和遗传编程的原代人T细胞

2025-10-210
OA
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study

从ide-cel早期复发后使用靶向BCMA的双特异性抗体治疗效果不佳:一项法国真实世界研究

2025-09-200
OAAI
Molecular profiling and risk stratification in solitary bone plasmacytoma

单发性骨浆细胞瘤的分子分型与风险分层

Leukemia
IF13.4
2025-09-110
PRE
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma

NGS-based靶向测序指导多发性骨髓瘤的风险适应性及分子靶向治疗决策

2025-08-260
OAAI
Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years

venetoclax在真实世界经验中的安全性:来自法国全国药物警戒数据库的数据,涵盖5年内血液系统恶性肿瘤的所有适应症。

2025-07-290
OA
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study

基于抗CD38的联合方案在多发性骨髓瘤中的真实世界再治疗:来自Emmy队列研究的结果

2025-05-210
OAAI
Inflammatory Waldenstrom Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

炎症性华氏巨球蛋白血症与克隆性造血相关:一项多中心队列研究

BLOOD
IF23.1
2024-11-050
PRE
Immunological Predictive Markers of Response to Idecabtagene Vicleucel Therapy in Multiple Myeloma : A Real-World Experience from St Louis Hospital (France)

对Idecabtagene Vicleucel疗法应答的免疫学预测性标志物:来自法国圣路易医院的真实世界经验

BLOOD
IF23.1
2024-11-050
PRE
Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema

针对浆细胞的疗法可在严重或复发/难治性硬化性水肿患者中引起深刻的临床和持久反应

2024-07-310
OAAI
Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study
2023-08-163
OAAI
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
2023-04-209
OAAI